The National Health Surveillance Agency (Anvisa) received, this Wednesday (16), in Brasília, a request from Pfizer for emergency use of the drug against Covid-19 Paxlovid (nirmatrelvir and ritonavir).
According to the pharmaceutical, studies show that, when administered at the beginning of the infection, Paxlovid, which is of the antiviral type and for oral use, has the ability to reduce cases of hospitalization and deaths. The data will be analyzed by Anvisa.
“The evaluation period for the emergency and temporary use of medication against Covid-19 is up to 30 days. The analysis does not consider the time of the process in technical requirement status, which is when the laboratory needs to answer technical questions made by the agency in the process”, explained Anvisa, in a press release.
The first 24 hours of analysis will be used to screen the process and verify that the necessary documents are available. If important information is missing, the agency can request it from the laboratory. On January 19, Anvisa and the laboratory had already held a pre-submission meeting for the product, a stage prior to the company’s formal submission of the order.
Chad-98Weaver, a distinguished author at NewsBulletin247, excels in the craft of article writing. With a keen eye for detail and a penchant for storytelling, Chad delivers informative and engaging content that resonates with readers across various subjects. His contributions are a testament to his dedication and expertise in the field of journalism.